Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup

More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The median duration of follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) had tumours with greater than 10 fmol mg-1 I125-EGF binding (EGFr+) and 47% (109) and cystolic ER concentrations greater than 5 fmol mg-1 (ER+), with a marked inverse relationship between EGFr and ER (P less than 0.00001). In a univariate analysis EGFr was second only to axillary node status as a prognostic marker for all patients both in terms of relapse-free and overall survival (P less than 0.001, log rank). For patients with histologically negative axillary nodes EGFr was superior to ER in predicting relapse and survival (P less than 0.01 and P less than 0.005 respectively compared to P less than 0.1 and P less than 0.1, log rank). In a multivariate (Cox model) analysis only EGFr, out of EGFr, ER, size and grade, was predictive for either relapse-free or overall survival for patients with node-negative disease (P = 0.05 and P = 0.026 respectively). EGFr has been shown to be a marker of poor prognosis for patients with node-negative breast cancer. Since patients with EGFr+ tumours are unlikely to respond to hormone therapy it may be possible to select them for trials of systemic adjuvant chemotherapy.

Abstract licence: CC BY

1. 1.

   Bonadonna G., Rossi A., Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. Lancet. 1985;1(8435):976-977.

   Not in our library10.1016/s0140-6736(85)91740-4 (opens in a new tab)

2. 2.

   Bonadonna G., Valagussa P. Current status of adjuvant chemotherapy for breast cancer. Semin Oncol. 1987;14(1):8-22.

   Not in our library

3. 3.

   Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989;320(10):627-633.

   Not in our library10.1056/nejm198903093201003 (opens in a new tab)

4. 4.

   Cooke T., George D., Shields R., Maynard P., Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979;1(8124):995-997.

   Not in our library10.1016/s0140-6736(79)92752-1 (opens in a new tab)

5. 5.

   Crawford D., Cowan S., Hyder S., McMenamin M., Smith D., Leake R. New storage procedure for human tumor biopsies prior to estrogen receptor measurement. Cancer Res. 1984;44(6):2348-2351.

   Not in our library

6. 6.

   The cancer research campaign (King's/Cambridge trial for early breast cancer: Clinico-pathological aspects · 1982

7. 7.

   Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52(9):1551-1557.

   Not in our library10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3 (opens in a new tab)

8. 8.

   Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479-484.

   Not in our library10.1056/nejm198902233200802 (opens in a new tab)

9. 9.

   Fisher B., Redmond C., Dimitrov N. V., Bowman D., Legault-Poisson S., Wickerham D. L., Wolmark N., Fisher E. R., Margolese R., Sutherland C. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320(8):473-478.

   Not in our library10.1056/nejm198902233200801 (opens in a new tab)

10. 10.

    Fisher B., Redmond C., Fisher E. R., Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988;6(7):1076-1087.

    Not in our library10.1200/jco.1988.6.7.1076 (opens in a new tab)

11. 11.

    Fisher B., Redmond C., Fisher E. R., Wolmark N. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr. 1986;(1):35-43.

    Not in our library

12. 12.

    Fisher B., Redmond C., Poisson R., Margolese R., Wolmark N., Wickerham L., Fisher E., Deutsch M., Caplan R., Pilch Y. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(13):822-828.

    Not in our library10.1056/nejm198903303201302 (opens in a new tab)

13. 13.

    Leake R. E., Laing L., Calman K. C., Macbeth F. R., Crawford D., Smith D. C. Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer. 1981;43(1):59-66.

    Not in our library10.1038/bjc.1981.8 (opens in a new tab)

14. 14.

    Mansour E. G., Gray R., Shatila A. H., Osborne C. K., Tormey D. C., Gilchrist K. W., Cooper M. R., Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989;320(8):485-490.

    Not in our library10.1056/nejm198902233200803 (opens in a new tab)

15. 15.

    Nicholson S., Halcrow P., Sainsbury J. R., Angus B., Chambers P., Farndon J. R., Harris A. L. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer. 1988;58(6):810-814.

    Not in our library10.1038/bjc.1988.315 (opens in a new tab)

16. 16.

    Nicholson S., Sainsbury J. R., Halcrow P., Chambers P., Farndon J. R., Harris A. L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet. 1989;1(8631):182-185.

    Not in our library10.1016/s0140-6736(89)91202-6 (opens in a new tab)

17. 17.

    Nicholson S., Sainsbury J. R., Needham G. K., Chambers P., Farndon J. R., Harris A. L. Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer. 1988;42(1):36-41.

    Not in our library10.1002/ijc.2910420108 (opens in a new tab)

18. 18.

    Padmanabhan N., Howell A., Rubens R. D. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet. 1986;2(8504):411-414.

    Not in our library10.1016/s0140-6736(86)92131-8 (opens in a new tab)

19. 19.

    Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples · 1977

20. 20.

    Pérez R., Pascual M., Macías A., Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1984;4(3):189-193.

    Not in our library10.1007/bf01806484 (opens in a new tab)

21. 21.

    Ríos M. A., Macías A., Pérez R., Lage A., Skoog L. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res. 1988;8(1):173-176.

    Not in our library

22. 22.

    Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1(8547):1398-1402.

    Not in our library10.1016/s0140-6736(87)90593-9 (opens in a new tab)

23. 23.

    Sainsbury J. R., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985;1(8425):364-366.

    Not in our library10.1016/s0140-6736(85)91385-6 (opens in a new tab)

24. 24.

    Silvestrini R., Daidone M. G., Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer. 1985;56(8):1982-1987.

    Not in our library10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i (opens in a new tab)

25. 25.

    Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.

    Not in our library10.1126/science.3798106 (opens in a new tab)

26. 26.

    Valagussa P., Bonadonna G., Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978;41(3):1170-1178.

    Not in our library10.1002/1097-0142(197803)41:3<1170::aid-cncr2820410355>3.0.co;2-i (opens in a new tab)

27. 27.

    Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49(8):2087-2090.

    Not in our library

• Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population · 2014

  Not checked

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.